Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma

NCT01875653 is registered in ClinicalTrials.gov with Lisata Therapeutics, Inc. as lead sponsor.

NCT NCT01875653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01875653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma
Lead sponsor
Lisata Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2014
Completion date
January 31, 2016
Enrollment
4 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii melanoma, stage iv melanoma